NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Morgan Stanley from Underweight to Overweight. $35 price target. Inflection in utility coal stockpiles could come sooner.
upgraded at FBR to Outperform. $20 price target. Company is gaining market share and should not see peak earnings until 2011.
upgraded at Citigroup from Hold to Buy. $97 price target. Company should have sustained production growth and benefit from higher oil prices.
upgraded at Goldman to Buy. $35 price target. Company is leveraged to higher telecom spending.
upgraded at Goldman from Neutral to Buy. $23 price target. Estimates also raised, as the LCD cycle has likely bottomed.
upgraded at Deutsche Bank from Hold to Buy. $24 price target. Estimates should move higher, given strong TV and PC demand.
downgraded at Goldman to Hold. $48 price target. Stock is up 47% over the past year.
upgraded at UBS from Neutral to Buy. $46 price target. Company should benefit from higher capital spending in Taiwan.
( MFE) upgraded at UBS from Neutral to Buy. $46 price target. Stock is down 12% over the past three months and the company is seeing strong future business indicators.
downgraded at Goldman from Buy to Neutral. Company has proved to be more sensitive to interest rates.
downgraded at UBS from Buy to Neutral. Valuation call, based on a $27 price target.
rated new Overweight at Morgan Stanley. $35 price target. Company can generate significant free cash flow and generate shareholder value.
upgraded at Goldman to Buy. $10 price target. Company is leverage to discretionary sales growth in the consulting segment, as well as improving ad trends.
upgraded at UBS from Neutral to Buy. $52 price target. Estimates also raised, to reflect earnings power of higher affiliate fees.
upgraded at FBR from Market Perform to Outperform. $16 price target. The company is positioned well to grow in the current semi test-equipment cycle.
( WFSL) downgraded at FBR from Outperform to Market Perform. $22 price target. Valuation call, as the recent FDIC-assisted acquisition could disappoint some investors.
STOCK COMMENTS / EPS CHANGES
estimates lowered at UBS through 2010. Now seeing lower market share for the Taxus stent. Buy rating and $10 price target.
numbers increased at Citigroup. Estimates were raised through 2012. Company is at an inflection point for same-store sales. Buy rating and new $43 price target.
added to Top Picks Live list at Citigroup. Company has several potential catalysts over the next few quarters. Buy rating and new $14.50 price target.
numbers increased at FBR. Shares of FSLR now seen reaching $100. Estimates also raised, to match the company's new guidance. Underperform rating.
numbers boosted at FBR. Shares of KLAC now seen reaching $45. Estimates also raised, to reflect stronger bookings. Market Perform rating.
numbers boosted at Citigroup. Shares of ONNN now seen reaching $14. Estimates also raised, to reflect higher order activity. Buy rating.
numbers raised at Morgan Stanley. Estimates were boosted through 2011. Production growth could lead to higher earnings. Overweight rating and new $65 price target.
price target boosted at BofA/Merrill to $71 from $68. 2010 and 2011 EPS estimates increased to $2.95 and $3.70, respectively. Maintain Buy rating.
This article was written by a staff member of TheStreet.com.